In this CE activity, experts in the field examine innovations in imaging and vitreoretinal surgery that can improve the diagnosis and management of retinal diseases, review the evidence on the safety and efficacy of sustained steroids and durable anti-vascular endothelial growth factor (VEGF) therapeutic regimens in the management of retinal vascular disorders, assess emerging advances in the use of gene therapy for retinal diseases, as well as evaluate new advances in the treatment of uveitis.
- Provider:Vindico Medical Education, LLC
- Activity Link: https://cme.healio.com/retinacme/retinal-vascular-diseases/20240305/retina360-advances-in-the-management-of-retinal-diseases/overview
- Start Date: 2024-03-31 05:00:00
- End Date: 2024-03-31 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.25 hours
- Commercial Support: Source: Alcon Vision, LLC - Amount: 3000.0 - Is Kind Support: False Source: Alimera Sciences, Inc. - Amount: 10400.0 - Is Kind Support: False Source: Genentech, a member of the Roche Group - Amount: 6500.0 - Is Kind Support: False Source: Janssen Pharmaceuticals, Inc., administered by Janssen Global Services, LLC - Amount: 8945.0 - Is Kind Support: False Source: Regeneron Pharmaceuticals, Inc - Amount: 9100.0 - Is Kind Support: False Source: REGENXBIO Inc. - Amount: 7045.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest